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 Bisphosphonates are potent inhibitors of osteoclast-mediated bone 
resorption and have demonstrated clinical utility in the palliative 
treatment of patients with bone metastases ( 1 ). There is now exten-
sive in vivo preclinical evidence that bisphosphonates can reduce 
skeletal tumor burden and inhibit the formation of bone metastases 
in animal models ( 2 ). Several mechanisms have been proposed to 
explain these observations. For example, bisphosphonates may ren-
der the bone a less favorable microenvironment for tumor cell colo-
nization by reducing osteoclast-mediated bone resorption, which, 
in turn, would deprive tumor cells of bone-derived growth factors 
released from the bone matrix ( 3 , 4 ). In addition, bisphosphonates 
appear to have direct antitumor effects ( 2 ). Bisphosphonates have 
been shown to inhibit tumor cell adhesion, invasion, and prolifera-
tion, and they induce apoptosis of a variety of human tumor cell 
lines in vitro ( 2 ). Bisphosphonates also inhibit tumor growth in vivo 
through antiangiogenic, anti-invasive, and immunomodulatory 
activities ( 2 ). However, the experimental conditions that have been 
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 ARTICLE 
 Antitumor Effects of Clinical Dosing Regimens of 
Bisphosphonates in Experimental Breast Cancer 
Bone Metastasis 
 Florence  Daubiné ,  Céline  Le Gall ,  Juerg  Gasser ,  Jonathan  Green ,  Philippe  Clézardin 
  Background  Bisphosphonates exhibit direct antitumor activity in animal models, but only at high doses that are incom-
patible with the clinical dosing regimens approved for the treatment of cancer patients with skeletal 
metastases. We compared the antitumor effects of clinical dosing regimens of the bisphosphonates zole-
dronic acid and clodronate in a mouse model of bone metastasis. 
  Methods  Mice (n = 6 – 10 per group) were treated with zoledronic acid, clodronate, or vehicle starting before (preven-
tive protocols) or after (treatment protocols) intravenous injection with human B02/GFP.2 breast cancer 
cells, which express green fluorescent protein (GFP) and luciferase and metastasize to bone. Zoledronic 
acid was given as daily, weekly, or single doses at a cumulative dose of 98 – 100  µ g/kg body weight, equiv-
alent to the 4-mg intravenous dose given to patients. Clodronate was given as a daily dose (530  µ g/kg/
day), equivalent to the daily 1600-mg oral clinical dose given to patients. Bone destruction was measured 
by radiography, x-ray absorptiometry or tomography, and histomorphometry (as the ratio of bone volume 
to tissue volume). Skeletal tumor burden was measured by histomorphometry (as the ratio of tumor bur-
den to soft tissue volume [TB/STV]) and luciferase activity. All statistical tests were two-sided. 
  Results  In treatment protocols, daily clodronate was less effective at decreasing the TB/STV ratio than daily (53% 
versus 87%, difference = 34%, 95% confidence interval [CI] = 16% to 44%,  P <.001) or weekly (53% versus 
90%, difference = 37%, 95% CI = 19% to 46%,  P <.001) zoledronic acid – dosing regimens. Compared with 
vehicle, a single dose of zoledronic acid decreased tumor burden by only 16% (95% CI = 9% to 22%, 
 P <.001). In preventive protocols, daily clodronate and daily or weekly zoledronic acid decreased the 
TB/STV ratio by 49% (95% CI = 40% to 57%,  P = .006), 83% (95% CI = 68% to 98%,  P <.001), and 66% (95% 
CI = 47% to 84%,  P <.001), respectively, compared with vehicle, whereas a single dose of zoledronic acid 
decreased tumor burden by only 13% (95% CI =  − 2% to 28%,  P = .84). Mice treated with a daily preventive 
regimen of clodronate or with a daily or weekly preventive regimen of zoledronic acid showed a decreased 
B02/GFP.2 cell tumor burden compared with vehicle, whereas a single preventive dose of zoledronic acid 
had no effect. 
  Conclusion  Daily or repeated intermittent therapy with clinical doses of bisphosphonates inhibits skeletal tumor 
growth in a mouse model. 
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used to study the efficacy of bisphosphonates in tumor-bearing ani-
mals are far removed from the conditions that have been used to 
treat patients with bone metastases ( 2 ). For example, the high doses 
of bisphosphonates that have been used in most animal studies 
are incompatible with the clinical dosing regimens that have been 
approved for the treatment of cancer patients with skeletal metas-
tases. Moreover, the bisphosphonate-dosing regimens that have 
been used in clinical trials to date have shown no convincing anti-
tumor effects ( 1 , 3 ). Thus, it is important to determine if a clinically 
relevant dosing regimen of bisphosphonate can achieve meaningful 
antitumor effects in animal models of bone metastasis. 
 We used a mouse model of human breast cancer bone metasta-
sis to examine the effects of different dosing regimens with two 
bisphosphonates, zoledronic acid and clodronate, on osteolysis and 
skeletal tumor growth. 
 Materials and Methods 
 Bisphosphonates 
 Clodronate (dichloromethylene bisphosphonic acid) and zoledronic 
acid [1-hydroxy-2-(1H-imidazole-1-yl)ethylidene-bisphosphonic 
acid], as the disodium salts, were provided by Novartis Pharma AG 
(Basle, Switzerland). These compounds were dissolved in water and 
stored at 4 °C. 
 Mouse Model of Bone Metastasis 
 All procedures involving mice including their housing and care, the 
method by which they were killed, and all experimental protocols 
were conducted in accordance with a code of practice established 
by the Experimentation Review Board from the Laennec School 
of Medicine. This study was monitored on a routine basis by the 
attending veterinarian to ensure continued compliance with the 
proposed protocols. Four-week-old female BALB/c athymic 
(nu/nu) mice were purchased from Charles River (St Germain sur 
l’Arbresle, France). The bone metastasis experiments in mice were 
conducted as previously described ( 5 , 6 ) using B02 cells, a subpopu-
lation of the human MDA-MB-231 breast cancer cell line that was 
selected for the high efficiency with which it metastasizes to bone 
after intravenous inoculation ( 5 ). We specifically used B02 cells 
that had been stably transfected with the genes encoding green flu-
orescent protein (GFP) and luciferase (B02/GFP.2 cells); the char-
acteristics of this cell line were described elsewhere ( 6 ). On day 0, 
B02/GFP.2 cells (5 × 10 5 cells in 100  µ L of phosphate-buffered 
saline [PBS]) were injected into the tail vein of mice anesthetized 
with 130 mg/kg ketamin and 8.8 mg/kg xylazin. In this model, mice 
usually develop bone metastases 18 days after tumor cell injection, 
as judged by radiography ( 6 ). For the treatment protocols (see 
“Dosing Regimens and Experimental Protocols”), mice were ana-
lyzed by radiography on day 18, and the area of osteolytic lesions 
on the skeleton of each animal was measured. Tumor-bearing ani-
mals were then distributed among the different treatment groups 
(n = 6 – 10 mice per group) to balance these groups for the extent 
of bone destruction at baseline. For the preventive protocols (see 
“Dosing Regimens and Experimental Protocols”), mice were ran-
domly assigned to treatment groups (n = 6 – 10 mice per group) 
1 day before B02/GFP.2 tumor cell injection. For both protocols, 
on day 32 after tumor cell inoculation, radiographs of anesthetized 
mice were taken with the use of MIN-R2000 film (Kodak, 
Rochester, NY) in an MX-20 cabinet X-ray system (Faxitron X-ray 
Corp, Wheeling, IL). Osteolytic lesions were identified on radio-
graphs as demarcated radiolucent lesions in the bone. The area of 
the osteolytic lesions was measured using a Visiolab 2000 comput-
erized image analysis system (Explora Nova, La Rochelle, France), 
and the extent of bone destruction per animal was expressed in 
square millimeters, as described previously ( 5 , 6 ). Anesthetized mice 
were killed by cervical dislocation after radiography on day 32. 
 Dosing Regimens and Experimental Protocols 
 The bisphosphonate doses we used were calculated on the basis of 
the current clinical doses that have been approved for the treatment 
of cancer patients with skeletal metastases (i.e., for zoledronic acid, 
4 mg via intravenous injection every 3 – 4 weeks; for clodronate, 
1600 mg taken orally daily), using an average body weight of 60 kg 
for patients and an oral bioavailability of 2% for clodronate ( 7 ). 
Based on an average body weight of 20 g for 4-week-old mice, clo-
dronate was administered to mice at a dosage of 530  µ g/kg body 
weight/day for both the treatment and preventive protocols ( Fig. 1 ). 
For zoledronic acid, we used three dosing regimens (daily, weekly, 
and single) for both the treatment and preventive protocols ( Fig. 1 ). 
Zoledronic acid was administered to mice at a daily dose of 3 and 
7  µ g/kg body weight for the preventive and treatment protocols, 
respectively, and a weekly dose of 20 and 50  µ g/kg body weight in 
the preventive and treatment protocols, respectively. However, the 
same total cumulative dose of zoledronic acid was given to each 
mouse (i.e., 98 – 100  µ g/kg body weight), regardless of the protocol 
or dosing regimen, which enabled us to directly compare the effi-
cacy of zoledronic acid among the different dosing regimens and 
the two different protocols. This dose (100  µ g/kg) is theoretically 
 CONTEXT AND CAVEATS 
 Prior knowledge 
 At high doses, bisphosphonates exhibit antitumor properties in 
animal models. However, the high doses of bisphosphonates used 
in animals are incompatible with approved treatment regimens for 
patients, and the bisphosphonate doses that are approved for 
patients do not have convincing antitumor effects. 
 Study design 
 In vivo study of clinical dosing regimens of bisphosphonates in a 
mouse model of breast cancer cell metastasis to bone. 
 Contribution 
 Bisphosphonates administered at low dosages on a daily or weekly 
dosing schedule were shown to inhibit skeletal tumor growth in a 
mouse model of bone metastasis. 
 Implications 
 Continuous or frequent intermittent low-dose therapy with bisphos-
phonates may facilitate the prolonged exposure of bone marrow to 
these drugs, thus enabling a direct effect on tumor cells that reside 
in bone. 
 Limitations 
 The mouse model does not recapitulate all steps required for spon-
taneous metastasis of breast cancer cells to bone and does not take 
into account the role of the immune system. 
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equivalent to the clinical dose of 6 mg every 3 – 4 weeks; the actual 
dose given to patients is 4 mg. However, zoledronic acid in the com-
mercial clinical vial (free acid monohydrate) has a lower molecular 
weight than the pure research-grade substance (disodium salt, 4.75 
hydrate) used in this study. Because of the difference in molecular 
weights between the free acid monohydrate and the disodium salt, a 
4-mg clinical dose of zoledronic acid is equivalent to 5.9 mg of pure 
research-grade substance. A total cumulative dose of 100  µ g/kg was 
therefore chosen to adjust for the higher molecular weight of the 
pure research-grade substance. All doses of each bisphosphonate 
were administered by subcutaneous injection in 100  µ L PBS (vehi-
cle). Control mice received a daily treatment with vehicle only. 
 Detection of Luciferase-Expressing Tumor Cells 
in Bone Lysates 
 B02/GFP.2 cells were inoculated intravenously into mice (5 × 10 5 
cells in 100  µ L of PBS). Mice injected intravenously with B02/
GFP.2 cells and treated on the three preventive protocols with 
zoledronic acid, clodronate, or vehicle were killed 14 days after 
tumor cell inoculation (n = 4 – 6 mice per group) and analyzed by 
radiography. None of these mice had radiographic evidence of 
bone destruction on the day they were killed. To produce a bone 
extract for each mouse, we harvested both tibiae, snap froze the 
limbs in liquid nitrogen, and crushed them together in 2 mL of 
lysate buffer (25 mM Tris-phosphate, pH 7.8, 2mM dithiothreitol, 
2mM EDTA, 1% [vol/vol] Triton X-100, and 5 mg/mL lysozyme 
[Promega, Madison, WI]). We mixed 30  µ L of bone extract of 
each mouse at room temperature with 100  µ L of beetle luciferin 
(Promega) and then measured the luciferase activity of the mixture 
with the use of an automated luminometer (Lumat LB 9507; 
Berthold Technologies, Thoiry, France). Results are expressed as 
relative light units (RLUs). 
 Bone Mineral Density Measurement 
 Vehicle- and bisphosphonate-treated mice bearing radiographically 
confirmed tumors (n = 6 – 10 mice per group) were killed on day 32 
after tumor cell inoculation for both protocols, and both hind limbs 
from each animal were dissected and fixed in 70% (vol/vol) alcohol. 
We measured the bone mineral density of tibiae with radiographic 
evidence of osteolytic lesions by dual-energy x-ray absorptiometry 
scanning with the use of a PIXI-mouse densitometer (Lunar Corp, 
Copenhagen, Denmark) or by peripheral quantitative computed 
tomography with the use of an XCT Research SA+ scanner (Stratec 
Medizintechnik, Pforzheim, Germany) fitted with a 0.5-mm colli-
mator, as previously described ( 8 , 9 ). For the peripheral quantitative 
computed tomography, the measurement of bone mineral density 
in tibiae was performed on four different locations within the proxi-
mal tibial metaphysis (S1 – S4, with S1 being the closest to the 
growth plate). Only the data obtained at the S1 location are shown 
in this study because this region is highly vascularized and is the 
site where osteolytic lesions start to develop. Results obtained using 
dual-energy x-ray absorptiometry and peripheral quantitative com-
puted tomography are expressed as milligram per square centimeter 
and milligram per cubic centimeter, respectively. 
 Bone Histology and Histomorphometry 
 Bone histology and histomorphometric analysis of bone tissue sec-
tions were performed as previously described ( 5 , 6 ). Briefly, vehicle- 
and bisphosphonate-treated tumor-bearing mice (n = 6 – 10 mice per 
group) were killed on day 32 after tumor cell inoculation for both 
protocols, and both hind limbs from each animal were dissected, 
fixed in 80% (vol/vol) alcohol, dehydrated, and embedded in meth-
ylmethacrylate. A microtome (Polycut E; Reichert-Jung, Heidelberg, 
Germany) was used to cut 7- µ m-thick sections of undecalcified long 
bones, and the sections were stained with Goldner’s trichrome 
( 5 , 6 ). Histologic and histomorphometric analyses were performed 
on Goldner’s trichrome – stained longitudinal medial sections of 
tibial metaphysis with the use of a computerized image analysis sys-
tem (Visiolab 2000), as previously described ( 5 ,  6 ). Histomorpho-
metric measurements (i.e., bone volume to tissue volume [BV/TV] 
and tumor burden to soft tissue volume [TB/STV] ratios) were 
performed in a standard zone of the tibial metaphysis, situated at 
0.5 mm from the growth plate, including cortical and trabecular 
bones. The BV/TV ratio represents the percentage of bone tissue. 
The TV/STV ratio represents the percentage of tumor tissue. 
 Statistical Analysis 
 All data were analyzed with the use of StatView software (version 
5.0; SAS Institute Inc, Cary, NC). Pairwise comparisons were 
carried out by performing a nonparametric Mann – Whitney  U test. 
 P  values less than .05 were considered statistically significant. All 
 statistical tests were two-sided. 
  
 Fig. 1 .  Summary of treatment and preventive protocols for bisphos-
phonates in mouse model of human B02 breast cancer cell metastasis 
to bone. B02 cells were inoculated intravenously into 4-week-old female 
BALB/c nude mice on day 0 (D0). In the treatment protocols, bisphos-
phonates were administered by subcutaneous injection beginning on 
day 18 (D18) after tumor cell inoculation, at which time the mice had 
developed bone metastases. In the preventive protocols, bisphospho-
nates were administered by subcutaneous injection beginning 1 day 
before tumor cell inoculation (D-1). In both protocols, zoledronic acid 
(ZOL) was administered daily, weekly, or once (on day 18 in the treat-
ment protocol and on day 1 in the preventive protocol); the total cumu-
lative dose of ZOL was 98 – 100  µ g/kg. For the daily dosage, ZOL was 
administered at a dose of 3 and 7  µ g/kg in the preventive and treatment 
protocols, respectively. A weekly dose of 20 and 50  µ g/kg of ZOL was 
used for the preventive and treatment protocols, respectively. 
Clodronate (CLO) was administered daily at a dose of 530  µ g/kg in both 
the treatment and preventive protocols. The mice were killed 32 days 
after tumor cell inoculation. 
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 Results 
 Effects of Zoledronic Acid and Clodronate on the 
Progression of Established Breast Cancer Bone 
Metastases (Treatment Protocols) 
 We used a mouse model of human breast cancer bone metastasis in 
which animals display radiographic evidence of osteolytic lesions in 
hind limbs 18 days after tumor cell injection ( 5 , 6 ). We first com-
pared the effects of different dosing regimens of zoledronic acid 
and a daily dosing regimen of clodronate on the progression of 
established bone metastases by using a treatment protocol in which 
drug administration to tumor-bearing mice was initiated on day 
18 after tumor cell injection ( Fig. 1 ). For all three regimens involving 
zoledronic acid (i.e., daily, weekly, and single), the total cumulative 
dose (administered by subcutaneous injection) was 98 – 100  µ g/kg 
body weight, which we calculated was equivalent to the 4-mg clini-
cal intravenous dose given to breast cancer patients on the basis of 
body weight. For the daily regimen involving clodronate, the dos-
age of 530  µ g/kg/day (also administered by subcutaneous injection) 
was similarly calculated to be equivalent to a clinical oral dose of 
1600 mg/day (assuming an oral bioavailability of 2%) ( 7 ). 
 Radiographic analysis on day 32 after tumor cell injection 
revealed that tumor-bearing mice treated with a single dose of 
zoledronic acid had osteolytic lesions that were 52% (95% conﬁ -
dence interval [CI] = 37% to 67%,  P <.001) smaller than those of 
tumor-bearing mice treated with the vehicle ( Table 1 and  Fig. 2 ). 
Similarly, tumor-bearing mice treated with daily or weekly dosing 
regimens of zoledronic acid had osteolytic lesions that were 66% 
(95% CI = 56% to 76%,  P <.001) and 50% (95% CI = 13% to 83%, 
 P = .04) smaller, respectively, than those of vehicle-treated animals 
( Table 1 and  Fig. 2 ). The inhibitory effect of zoledronic acid on 
the progression of osteolytic lesions did not differ statistically sig-
niﬁ cantly among the different dosing regimens ( Table 1 ). In addi-
tion, hind legs bearing metastases from mice treated with each of 
the three zoledronic acid – dosing regimens had statistically signiﬁ -
cantly higher bone mineral density than those from mice treated 
with vehicle ( Table 1 ). Compared with vehicle, the daily, weekly, 
and single regimens of zoledronic acid increased the bone mineral 
density by 24% (95% CI = 18% to 31%,  P <.001), 16% (95% CI = 
10% to 23%,  P = .004), and 14% (95% CI = 7% to 20%,  P = .01), 
respectively ( Table 1 ). Moreover, the daily dosing regimen with 
zoledronic acid was statistically signiﬁ cantly more effective than a 
single dosing of zoledronic acid at increasing the bone mineral 
density (633 mg/cm 3 versus 579 mg/cm 3 , difference = 54 mg/cm 3 , 
95% CI = 9 to 99 mg/cm 3 ,  P = .02). By contrast, the bone mineral 
density did not differ statistically signiﬁ cantly among the weekly 
and single dosing regimens. Daily clodronate was less effective 
than daily zoledronic acid (580 mg/cm 3 versus 633 mg/cm 3 , 
 difference = 53 mg/cm 3 , 95% CI = 3 to 103 mg/cm 3 ,  P = .04) but 
similar to the weekly and single zoledronic acid – dosing regimens 
at increasing the bone mineral density . 
 Histomorphometric analysis of hind limbs with metastases 
showed that mice treated with each of the three regimens of zole-
dronic acid had statistically signiﬁ cantly higher BV/TV ratios 
(indicating a prevention of bone loss) than vehicle-treated mice. 
For example, the daily, weekly, and single regimens of zoledronic 
acid increased the BV/TV by 138% (95% CI = 126% to 150%), 
79% (95% CI = 67% to 89%), and 90% (95% CI = 82% to 98%), 
respectively, compared with vehicle ( P <.001 for all three regimens) 
( Table 1 and  Fig. 2 ). Moreover, mice treated with a daily zole-
dronic acid regimen had a statistically signiﬁ cantly higher BV/TV 
ratio than mice receiving a weekly or single dosing regimen of 
zoledronic acid (mean BV/TV for daily zoledronic acid: 41%, 
mean BV/TV for weekly zoledronic acid: 30%, mean BV/TV for 
single zoledronic acid: 32%; difference for daily versus weekly 
zoledronic acid = 11%, 95% CI = 9% to 14%,  P <.001; difference 
for daily versus single zoledronic acid = 9%, 95% CI = 7% to 11%, 
 P <.001). Mice treated with daily clodronate also had statistically 
signiﬁ cantly higher BV/TV ratios than vehicle-treated mice 
( Table 1 ). However, daily clodronate was less effective than daily 
zoledronic acid at increasing the BV/TV ratio (28% versus 41%, 
difference = 13%, 95% CI = 10% to 16%,  P <.001). 
 Compared with the vehicle, the daily and weekly regimens of 
zoledronic acid also substantially decreased the TB/STV ratio 
(a measure of the skeletal tumor burden) by 87% (95% CI = 75% 
to 93%,  P <.001) and 90% (95% CI = 80% to 94%,  P <.001), 
respectively, whereas a single dose of zoledronic acid decreased 
the TB/STV ratio by only 16% (95% CI = 9% to 22%,  P <.001 ) 
( Table 1 and  Fig. 2 ). Daily clodronate decreased the TB/STV ratio 
by 53% (95% CI = 39% to 64%,  P <.001) compared with vehicle 
( Table 1 and  Fig. 2 ). However, daily clodronate was statistically 
signiﬁ cantly less effective at decreasing skeletal tumor burden than 
the daily (53% versus 87%, difference = 34%, 95% CI = 16% to 
 Table 1 .  Effect of different dosing regimens of zoledronic acid and clodronate on the progression of established breast cancer 
bone metastases * 
 Bisphosphonate 
or vehicle 
(dosing schedule)
Radiography Bone mineral density Histomorphometry 
 No. of 
mice
mm 2 /mouse 
(95% CI)  P 
No. of legs 
with bone 
metastasis
mg/cm 3 
(95% CI)  P 
No. of legs 
with bone 
metastasis
BV/TV, % 
(95% CI)  P 
TB/STV, % 
(95% CI)  P 
 Vehicle (daily) 27 9.7 (7.9 to 11.5)  – 11 510 (482 to 538)  – 22 17 (15 to 20)  – 96 (94 to 98)  – 
 ZOL (daily) 6 3.3 (2.4 to 4.3) <.001 9 633 (599 to 667) <.001 12 41 (40 to 43) <.001 12 (6 to 19) <.001 
 ZOL (weekly) 5 4.8 (1 to 8.6) .04 9 592 (552 to 631) .006 10 30 (29 to 32) <.001 10 (5 to 16) <.001 
 ZOL (single) 16 4.7 (3.2 to 6.1) <.001 8 579 (544 to 614) .001 16 32 (31 to 34) <.001 81 (76 to 87) <.001 
 CLO (daily) 6 3.5 (2.2 to 4.7) <.001 10 580 (539 to 621) .009 11 28 (25 to 32) <.001 45 (31 to 60) <.001 
 * Data are mean values from two to three independent experiments. All measurements were made 32 days after tumor cell injection.  P values (two-sided) are 
for pairwise comparisons with vehicle-treated control group using the Mann – Whitney  U test. ZOL = zoledronic acid; CLO = clodronate; CI = confidence interval; 
BV/TV = bone volume – to – tissue volume ratio; TB/STV = tumor burden – to – soft tissue volume ratio;  – = not applicable (referent). 
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44%,  P <.001) or weekly zoledronic acid – dosing regimens (53% 
versus 90%, difference = 37%, 95% CI = 19% to 46%,  P <.001). 
 Effects of Zoledronic Acid and Clodronate on the 
Formation of Breast Cancer Bone Metastases 
(Preventive Protocols) 
 We next compared the effects of the different dosing regimens of 
zoledronic acid and the daily dosing regimen of clodronate on the 
formation of breast cancer bone metastases by using a preventive 
protocol in which drug administration was initiated 1 day before 
tumor cell inoculation ( Fig. 1 ). We found that mice treated 1 day 
before tumor cell inoculation with a single dose of 100  µ g zole-
dronic acid/kg body weight had osteolytic lesions that were the 
same size as those of mice treated with vehicle ( Table 2 and  Fig. 2 ). 
The average area of osteolytic lesions was decreased by only 13% 
(95% CI =  − 2% to 28%,  P = .84) compared with the vehicle. By 
contrast, mice treated with the daily or weekly regimens of zole-
dronic acid beginning 1 day before tumor cell inoculation had 
osteolytic lesions that were 88% (95% CI = 81% to 95%) and 80% 
(95% CI = 71% to 90%), respectively, smaller than those of mice 
treated with vehicle ( P <.001 for both regimens). Moreover, mice 
treated with the daily or weekly regimens of zoledronic acid had 
statistically significantly smaller osteolytic lesions than mice treated 
with a daily regimen of clodronate (mean area of osteolytic lesion 
for daily zolodronic acid: 1.4 mm 2 ; weekly zoledronic acid: 2.1 mm 2 ; 
daily clodronate: 5.5 mm 2 ; difference for daily zoledronic acid ver-
sus daily clodronate = 4.1 mm 2 , 95% CI = 2.3 to 6 mm 2 ,  P <.001; differ-
e nce for weekly zoledronic acid versus daily clodronate = 3.4 mm 2 , 
95% CI = 1.2 to 5.6 mm 2 ,  P = .006) ( Table 2 and  Fig. 2 ). 
Radiographic analysis revealed the presence of dense transverse 
lines on the tibial metaphysis of mice treated with the weekly and 
single regimens of zoledronic acid ( Fig. 2 , arrowheads). 
 The bone mineral density of hind legs from mice treated with 
the daily or weekly regimens of zoledronic acid was statistically 
 Fig. 2 .  Radiographic and histologic 
analyses of hind limbs from mice 
treated on treatment or preventive pro-
tocols with zoledronic acid (ZOL) or 
clodronate (CLO). For each protocol, 
the  left panels show radiographs of 
hind limbs and the  right panels show 
micrographs of Goldner’s trichrome –
 stained sections of tibial metaphysis. 
All images were obtained from differ-
ent mice on day 32 after B02 breast 
cancer cell inoculation. The images 
shown are examples that best illustrate 
the effects of the treatments.  Arrows 
indicate osteolytic lesions.  Arrowheads 
indicate dense transversal metaphy-
seal lines on radiographs of hind limbs 
from mice that have received a single 
or weekly dose of zoledronic acid on a 
preventive protocol. For histologic tis-
sue sections, bone is stained  green 
whereas bone marrow and tumor cells 
( asterisk ) are stained  red . 
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signiﬁ cantly greater than that of mice treated with vehicle, with the 
single dose of zoledronic acid before tumor cell inoculation or with 
the daily regimen of clodronate ( Table 2 ). Histomorphometric 
analysis of metastasis-bearing hind limbs revealed that mice treated 
with the daily or weekly regimens of zoledronic acid had statisti-
cally signiﬁ cantly higher BV/TV ratios than mice treated with 
vehicle, whereas mice treated with the single dosing regimen of 
zoledronic acid did not ( Table 2 and  Fig. 2 ). For example, the daily 
and weekly regimens of zoledronic acid increased the BV/TV ratio 
by 180% (95% CI = 152% to 208%) and 103% (95% CI = 65% to 
142%), respectively, compared with vehicle ( P <.001 for both regi-
mens). The BV/TV ratio for mice treated with daily clodronate 
was 63% higher (95% CI = 43% to 83%,  P = .006) than that of 
vehicle-treated mice ( Table 2 ). However, mice treated with the 
daily or weekly regimens of zoledronic acid had statistically signiﬁ -
cantly higher BV/TV ratios than mice treated with the daily regi-
men of clodronate (34% versus 20%, difference = 14%, 95% CI = 
10% to 18%,  P <.001, and 25% versus 20%, difference = 5%, 95% 
CI = 0.5% to 9%,  P = .03, respectively). The daily and weekly regi-
mens of zoledronic acid also reduced the TB/STV ratio by 83% 
(95% CI = 68% to 98%) and 66% (95% CI = 47% to 84%), 
respectively, compared with vehicle ( P <.001 for both regimens). 
Daily clodronate also reduced the skeletal tumor burden by 49% 
(95% CI = 40% to 57%,  P = .006) compared with vehicle ( Table 2 
and  Fig. 2 ). However, mice treated with a daily clodronate regimen 
had a statistically signiﬁ cantly higher skeletal tumor burden than 
mice treated with a daily zoledronic acid regimen (30% versus 
10%, difference = 20%, 95% CI = 10% to 29%,  P <.001). 
 Our assessment of the histology of Goldner's trichrome – stained 
bones bearing metastatic lesions revealed that the reduction of 
skeletal tumor growth we observed with either bisphosphonate 
treatment was not associated with the concomitant invasion of soft 
tissues (muscle, tendon, or connective tissue) adjacent to bones 
( Fig. 2 ). 
 Effects of Zoledronic Acid and Clodronate on Tumor Cell 
Homing to Bone Marrow 
 The measurement of luciferase activity expressed by tumor cells is 
a highly sensitive and quantitative method to detect the early devel-
opment of bone metastases ( 10 ). Our use of B02 breast cancer cells 
that expressed a stably transfected gene encoding luciferase ( 6 ) 
allowed us to examine whether mice treated on the preventive 
 protocols with bisphosphonates displayed evidence of luciferase-
expressing B02/GFP.2 cells in bone extracts on day 14 after tumor 
cell inoculation, at which time there was no radiographic evidence 
of osteolytic lesions (data not shown). We assumed that detection 
of luciferase activity (expressed in RLUs) was an indication that B02 
breast cancer cells were present in the bone marrow. Bone extracts 
of hind limbs from vehicle-treated mice (n = 6) that had been inocu-
lated with tumor cells had a mean luciferase activity of 147 894 
RLUs (95% CI = 85 525 to 210 263 RLUs). By contrast, bone 
extracts of hind limbs from age-matched control mice (n = 5) that 
had not been inoculated with tumor cells had a very low (i.e., back-
ground) level of luciferase activity (443 RLUs, 95% CI = 238 to 648 
RLUs), further indicating that the detection of luciferase activity 
was inherent to the presence of inoculated tumor cells. 
 The mean luciferase activities of bone extracts from mice 
treated with the daily, weekly, or single dosing regimens of zole-
dronic acid were 86 911 RLUs (95% CI = 71 838 to 101 983 RLUs; 
n = 4 mice), 55 236 RLUs (95% CI = 41 474 to 68 998 RLUs; n = 
4 mice), and 152 692 RLUs (95% CI = 58 714 to 246 669 RLUs; 
n = 4 mice), respectively. Mice treated with the daily or weekly 
regimens of zoledronic acid had a statistically signiﬁ cantly lower 
B02 tumor burden than mice treated with the vehicle (mean lucif-
erase activity for daily zoledronic acid: 86 911 RLUs; weekly zole-
dronic acid: 55 236 RLUs; vehicle: 147 894 RLUs; difference for 
daily zoledronic acid versus vehicle = 60 983 RLUs, 95% CI = 
 − 9484 to 131 451 RLUs,  P = .01; difference for weekly zoledronic 
acid versus vehicle = 92 658 RLUs, 95% CI = 22 278 to 163 038 
RLUs,  P = .01). The mean luciferase activity measured in bone 
extracts from clodronate-treated mice was 46 693 RLUs (95% CI = 
16 124 to 71 261 RLUs; n = 3 mice), which was also statistically 
signiﬁ cantly lower than that of vehicle-treated mice (difference for 
clodronate versus vehicle = 104 201 RLUs, 95% CI = 19 633 to 
188 769 RLUs,  P = .02). By contrast, the mean luciferase activity of 
bone extracts from mice treated with the single dosing regimen of 
zoledronic acid was not statistically signiﬁ cantly different from 
that of vehicle-treated animals (152 692 versus 147 894 RLUs, dif-
ference = 4797 RLUs, 95% CI =  − 83 460 to 93 054 RLUs,  P = .67). 
 Discussion 
 There is a growing body of evidence from preclinical research 
showing that bisphosphonates exhibit antitumor activity, both 
in vitro and in vivo ( 2 ). However, there is much debate about the 
clinical relevance of these experimental findings because the high 
 Table 2 .  Effect of different dosing regimens of zoledronic acid and clodronate on the formation of breast cancer bone metastases * 
 Bisphosphonate 
or vehicle 
(dosing schedule)
Radiography Bone mineral density Histomorphometry 
 No. of 
mice
mm 2 /mouse 
(95% CI)  P 
No. of legs 
with bone 
metastasis
mg/cm 2 
(95% CI)  P 
No. of legs 
with bone 
metastasis
BV/TV, % 
(95% CI)  P 
TB/STV, % 
(95% CI)  P 
 Vehicle (daily) 17 11 (9.2 to 13)  – 6 77 (67 to 86)  – 11 12 (8 to 16)  – 59 (46 to 73)  – 
 ZOL (daily) 8 1.4 (0.6 to 2.1) .002 8 94 (85 to 104) .01 11 34 (30 to 37) .001 10 (1 to 19) .001 
 ZOL (weekly) 7 2.1 (1.1 to 3.2) .004 5 104 (91 to 117) .008 9 25 (20 to 29) .004 20 (8 to 31) .002 
 ZOL (single) 10 11 (9.7 to 12.4) .86 3 87 (83 to 91) .07 6 13 (10 to 16) .7 60 (41 to 78) .85 
 CLO (daily) 9 5.5 (3.7 to 7.3) .004 7 72 (68 to 76) .31 12 20 (17 to 22) .005 30 (24 to 35) .002 
 * Data are mean values from two to three independent experiments. All measurements were made 32 days after tumor cell injection.  P values (two-sided) are 
for pairwise comparisons with vehicle-treated control group using the Mann – Whitney  U test. ZOL = zoledronic acid; CLO = clodronate; CI = confidence interval; 
BV/TV = bone volume – to – tissue volume ratio; TB/STV = tumor burden – to – soft tissue volume ratio;  – = not applicable (referent). 
328   Articles | JNCI Vol. 99, Issue 4  |  February 21, 2007
doses of bisphosphonates used in most animal studies are incom-
patible with the dosing regimens that have been approved for the 
treatment of cancer patients with skeletal metastases. Given that 
the skeletal retention of bisphosphonates is related to the rate of 
bone turnover in breast cancer patients with bone metastases ( 11 ) 
and that bone turnover in rodents is three to five times higher than 
that in humans ( 12 ), it could be argued that a fivefold higher 
bisphosphonate dose in animal models of bone metastasis should 
mimic the clinical situation. Yet, most animal studies have used 
even higher doses of bisphosphonate ( 13 ). For example, in many 
animal models of multiple myeloma and breast and prostate can-
cers, it has been shown that zoledronic acid at total monthly cumu-
lative doses that range from 30 to 150 mg reduces skeletal tumor 
growth ( 13 ). By contrast, the approved monthly dose of zoledronic 
acid for the treatment of cancer patients with skeletal metastases is 
4 mg infused over 15 minutes; higher doses are not feasible because 
of concerns about renal toxicity ( 3 ). Therefore, we reasoned that a 
chemotherapeutic approach that emphasized dose density (i.e., the 
administration of a bisphosphonate over shorter treatment inter-
vals) rather than dose escalation could be an effective way to mini-
mize skeletal tumor burden in this mouse model of metastatic 
breast cancer, and perhaps, in the clinic. 
 Our results show that clinically relevant doses of bisphospho-
nates produced meaningful antitumor effects in an animal model 
of breast cancer bone metastasis, as long as the bisphosphonate was 
administered at a low dosage on a daily or weekly dosing schedule. 
Our results also suggest that, in the clinical setting, bisphospho-
nate therapy with a long dosing interval could reduce osteolysis by 
inhibiting bone resorption, whereas therapy with a more frequent 
dosing interval could also directly affect the growth of tumor cells 
resident in bone. Our contention that bisphosphonate therapy 
with a long dosing interval may inhibit cancer-induced bone loss is 
supported by our ﬁ nding that mice with established bone metasta-
ses that were treated on the treatment protocol with a single clini-
cal dose of zoledronic acid had less bone destruction, but not less 
skeletal tumor burden, than vehicle-treated animals. Moreover, 
the radiographic analysis of mice treated on the preventive proto-
cols with weekly zoledronic acid or the single dose of zoledronic 
acid clearly showed the presence of dense transverse lines on the 
tibial metaphysis. Similar dense metaphyseal lines were previously 
noted in children with severe osteogenesis imperfecta after cyclic 
administration of the bisphosphonate pamidronate, where they 
were thought to arise after temporary interruption of growth plate 
cartilage resorption at the time of a pamidronate infusion ( 14 ). 
In agreement with these ﬁ ndings ( 14 ), the metaphyseal lines we 
observed in the bones of mice in our breast cancer metastasis 
model consisted of trabecular bone that had not been destroyed 
because a single or weekly bisphosphonate administration had 
temporarily interrupted osteoclast-mediated bone resorption; 
when bone growth later resumed, the growth plate moved away 
from these horizontal trabeculae, which then became visible as 
dense transverse lines on radiographs. However, we surmise that, 
concomitant with bone growth, breast cancer cells may have 
started to stimulate osteoclast-mediated bone resorption, leading 
to bone destruction. Conversely, a daily treatment with zoledronic 
acid induced a continuous inhibition of bone resorption, leading to 
an almost complete inhibition of skeletal tumor burden. A contin-
uous daily treatment with clodronate also reduced skeletal tumor 
burden, although the extent of inhibition was much less than that 
observed with zoledronic acid. These results are in accordance 
with the “vicious cycle” theory ( 4 ), in which breast cancer cells 
stimulate osteoclast-mediated bone resorption and bone-derived 
growth factors released from resorbed bone stimulate tumor 
growth. The results also suggest that bisphosphonates (as exempli-
ﬁ ed here by zoledronic acid and clodronate) inhibit bone resorp-
tion, which subsequently deprives breast cancer cells of bone-derived 
growth factors that are required for tumor cell proliferation. 
 Aside from our observation that bisphosphonates may render 
the bone a less favorable microenvironment for tumor growth by 
reducing osteoclast-mediated bone resorption, we used a continu-
ous or frequent intermittent low-dose therapy with zoledronic acid 
to investigate whether bisphosphonates also have the potential to 
exert a direct antitumor effect in vivo. We found that although 
the different dosing regimens of zoledronic had similar inhibitory 
effects on bone resorption in the treatment protocols, only a daily 
or weekly regimen of zoledronic acid reduced skeletal tumor bur-
den. If bisphosphonate treatment decreased skeletal tumor burden 
solely by reducing bone loss, we would have expected the single-
dose regimen of zoledronic acid to have inhibited skeletal tumor 
growth more than what we observed. It is interesting that Gao et al. 
( 15 ) recently reported that a preventive treatment regimen with 
zoledronic acid (used at dosage of 30  µ g/kg/wk, which was similar 
to the 20  µ g/kg/wk dosage that we used) inhibited not only the 
formation of bone tumors in transgenic mice that spontaneously 
develop leukemia and osteolytic lesions but also the formation 
of soft tissue tumors. These ﬁ ndings ( 15 ) suggest that a frequent 
zoledronic acid dosage may directly inhibit tumor growth. Indeed, 
we showed that a daily or weekly preventive regimen of zoledronic 
acid or a daily preventive regimen of clodronate interfered with the 
homing of luciferase-expressing B02 breast cancer cells to bone 
in vivo. van der Pluijm et al. ( 10 ) also recently reported that preven-
tive treatment of nude mice with the bisphosphonate olpadronate 
(given in a daily clinical dosing regimen at 23  µ g/kg) inhibited the 
early development of luciferase-expressing MDA-MB-231 breast 
cancer cells (MDA-231-B/luc + ) in bone. However, in this animal 
model, the inhibitory effect of olpadronate on skeletal tumor 
growth was transient, and tumor growth eventually resumed 
(although there was a substantial reduction in osteolysis) ( 10 ). 
These results may be explained by the extramedullary growth of 
MDA-231-B/luc + cells that was observed in the surrounding soft 
tissues ( 10 ), which may have masked the inhibitory effect of olpa-
dronate on skeletal tumor burden. A similar masking of the inhibi-
tory effect of the bisphosphonate ibandronate on skeletal tumor 
burden has been observed in 5TGM1 and ARH-77 murine models 
of myeloma, in which tumor growth is not conﬁ ned to bone ( 2 ). 
Conversely, we found that when tumor growth is restricted to 
bone, as in our breast cancer model, a continuous dosing regimen 
of zoledronic acid or clodronate or a frequent intermittent dosing 
regimen of zoledronic acid reduced both the progression of oste-
olysis and the homing of tumor cells to bone. 
 Our results are reminiscent of those obtained in a randomized 
trial of dose-dense versus conventionally scheduled chemotherapy 
in the adjuvant treatment of node-positive breast cancer patients, 
in which dose density was found to be more effective than dose 
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escalation for reducing residual tumor burden ( 16 ). It is therefore 
possible that continuous or frequent intermittent low-dose therapy 
with zoledronic acid or clodronate allows prolonged exposure of 
the bone marrow to bisphosphonates, thus enabling a direct effect 
on tumor cells that reside in bone. The homing of tumor cells in 
bone likely involves early metastatic processes such as tumor cell 
invasion ( 4 ). In vitro, bisphosphonates inhibit breast cancer cell 
invasion ( 2 ). However, to our knowledge, there is no in vivo evi-
dence that bisphosphonates directly inhibit tumor cell invasion. 
A daily or weekly preventive regimen of zoledronic acid or a daily 
preventive regimen of clodronate could therefore inhibit the 
 homing of metastatic cells to bone by reducing tumor cell inva-
sion. Additional mechanisms, such as the inhibition of tumor cell 
extravasation and proliferation within the bone microenviron-
ment, may also be involved in reducing the homing of tumor cells 
to bone. For example, it was recently shown that the activation of 
bone turnover in athymic mice favored prostate cancer localiza-
tion and growth in the skeleton, whereas zoledronic acid treatment 
reduced the development of these skeletal lesions ( 17 ). A continu-
ous or frequent intermittent low-dose preventive therapy with 
zoledronic acid or clodronate could also reduce bone turnover in 
our animal model, thereby inhibiting the homing of B02 breast 
cancer cells in bone. Such potential inhibitory mechanisms using 
continuous or frequent intermittent bisphosphonate therapy merit 
a fuller investigation. 
 The main limitation of our study is that the bone metastases 
were induced by injecting human breast cancer cells into the sys-
temic circulation in immunocompromised mice. Such an approach 
does not recapitulate all the steps that are required for tumor cells 
to spread from the primary tumor to distant organs and does not 
take the role of the immune system into account. An animal model 
that more likely reﬂ ects the clinical reality does exist, in which 
mouse 4T1 breast cancer cells implanted in the mammary gland 
spontaneously metastasize to bone, lungs, and liver in immuno-
competent syngeneic mice ( 18 ). In that model, Hiraga et al. ( 18 ) 
found that zoledronic acid (used at a 60-mg total monthly cumula-
tive dose) reduced 4T1 metastasis to visceral organs and bones. 
It would be interesting to examine the effect of a continuous or 
frequent intermittent low-dose preventive bisphosphonate therapy 
on spontaneous metastasis in this animal model. 
 Our results provide some support for an adjuvant role of 
bisphosphonates in breast cancer. In this respect, it was recently 
reported that the addition of oral clodronate (1600 mg daily for 
2 years) to standard treatment for primary operable breast cancer 
statistically signiﬁ cantly reduced the risk of bone metastases by 
31% over a 5-year period ( 19 ). Two larger phase III trials of 
bisphosphonates as adjuvant therapy for primary breast cancer, 
each enrolling more than 3000 patients with early-stage breast 
cancer, are underway. The National Surgical Adjuvant Breast 
Project B-34 trial will determine whether oral clodronate (1600 
mg daily for 3 years) administered alone or in combination with 
chemotherapy and/or hormonal therapy reduces the incidence of 
skeletal and nonskeletal metastases or improves overall or relapse-
free survival. The Southwest Oncology Group 0307 trial will 
compare zoledronic acid (4 mg administered intravenously every 4 
weeks for 6 months, then every 3 months for 2.5 years), clodronate 
(1600 mg taken orally daily for 3 years), and the bisphosonate 
ibandronate (50 mg taken orally daily for 3 years) as adjuvant ther-
apy for primary breast cancer. The ﬁ rst results from these clinical 
trials are expected to be available in 2008. On the basis of our pre-
clinical results reported here and those obtained for clodronate 
and for dose-dense chemotherapy in clinical trials ( 16 , 19 ), we 
anticipate that the use of dose-dense bisphosphonate therapy as 
adjuvant treatment of primary breast cancer will decrease the risk 
of bone metastases. 
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